Eisai Receives Approval to Market Pariet Triple Formulation Pack
Eisai Receives Approval to Market Pariet Triple Formulation Packs Rabecure 400 and 800 and Rabefine, for Primary and Secondary H. Pylori Eradication Respectively, in Japan
Tokyo, Aug 21, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has received marketing authorization from Japan's Ministry of Health, Labour and Welfare for two types of triple formulation packs (combination packs) that contain its proton pump inhibitor Pariet (rabeprazole sodium) for Helicobacter pylori eradication.
The authorization approves Rabecure Pack 400 and Rabecure Pack 800, which package together individual blister sheets each containing a daily triple formulation dose of Pariet, amoxicillin hydrate and clarithromycin for primary H. pylori eradication, and Rabefine Pack, which similarly packages together individual blister sheets each containing a daily triple formulation dose of Pariet, amoxicillin hydrate and metronidazole for secondary H. pylori eradication.
In H. pylori eradication triple therapy with Pariet and two antimicrobial agents, successful eradication significantly depends on whether the patient properly adheres to the prescribed treatment regimen. Taking the incorrect dose or missing doses altogether can not only lead to reduced eradication rates but also to bacterial resistance and increased side effects. Both the primary and secondary eradication combination packs contain daily triple formulation doses of Pariet and two antimicrobial agents packaged in individual blister sheets and as such are expected to help ensure that H. pylori eradication therapy is carried out more appropriately and with greater certainty, improve patient drug compliance, and offer increased convenience in a medical setting.
Eisai believes that its Rabecure and Rabefine combination packs will further promote the proper use of agents used in H. pylori eradication and further contribute to increasing the benefits provided to patients with diseases associated with H. pylori.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net
Provider ID: 00027281